A phase 2b randomised trial of the candidate malaria vaccines FP9 ME-TRAP and MVA ME-TRAP among children in Kenya.

Philip Bejon, Jedidah Mwacharo, Oscar Kai, Tabitha Mwangi, Paul Milligan, Stephen Todryk, Sheila Keating, Trudie Lang, Brett Lowe, Caroline Gikonyo, Catherine Molyneux, Greg Fegan, Sarah C Gilbert, Norbert Peshu, Kevin Marsh, Adrian V S Hill
{"title":"A phase 2b randomised trial of the candidate malaria vaccines FP9 ME-TRAP and MVA ME-TRAP among children in Kenya.","authors":"Philip Bejon,&nbsp;Jedidah Mwacharo,&nbsp;Oscar Kai,&nbsp;Tabitha Mwangi,&nbsp;Paul Milligan,&nbsp;Stephen Todryk,&nbsp;Sheila Keating,&nbsp;Trudie Lang,&nbsp;Brett Lowe,&nbsp;Caroline Gikonyo,&nbsp;Catherine Molyneux,&nbsp;Greg Fegan,&nbsp;Sarah C Gilbert,&nbsp;Norbert Peshu,&nbsp;Kevin Marsh,&nbsp;Adrian V S Hill","doi":"10.1371/journal.pctr.0010029","DOIUrl":null,"url":null,"abstract":"<p><strong>Objective: </strong>The objective was to measure the efficacy of the vaccination regimen FFM ME-TRAP in preventing episodes of clinical malaria among children in a malaria endemic area. FFM ME-TRAP is sequential immunisation with two attenuated poxvirus vectors (FP9 and modified vaccinia virus Ankara), which both deliver the pre-erythrocytic malaria antigen construct multiple epitope-thrombospondin-related adhesion protein (ME-TRAP).</p><p><strong>Design: </strong>The trial was randomised and double-blinded.</p><p><strong>Setting: </strong>The setting was a rural, malaria-endemic area of coastal Kenya.</p><p><strong>Participants: </strong>We vaccinated 405 healthy 1- to 6-year-old children.</p><p><strong>Interventions: </strong>Participants were randomised to vaccination with either FFM ME-TRAP or control (rabies vaccine).</p><p><strong>Outcome measures: </strong>Following antimalarial drug treatment children were seen weekly and whenever they were unwell during nine months of monitoring. The axillary temperature was measured, and blood films taken when febrile. The primary analysis was time to a parasitaemia of over 2,500 parasites/mul.</p><p><strong>Results: </strong>The regime was moderately immunogenic, but the magnitude of T cell responses was lower than in previous studies. In intention to treat (ITT) analysis, time to first episode was shorter in the FFM ME-TRAP group. The cumulative incidence of febrile malaria was 52/190 (27%) for FFM ME-TRAP and 40/197 (20%) among controls (hazard ratio = 1.52). This was not statistically significant (95% confidence interval [CI] 1.0-2.3; p = 0.14 by log-rank). A group of 346 children were vaccinated according to protocol (ATP). Among these children, the hazard ratio was 1.3 (95% CI 0.8-2.1; p = 0.55 by log-rank). When multiple malaria episodes were included in the analyses, the incidence rate ratios were 1.6 (95% CI 1.1-2.3); p = 0.017 for ITT, and 1.4 (95% CI 0.9-2.1); p = 0.16 for ATP. Haemoglobin and parasitaemia in cross-sectional surveys at 3 and 9 mo did not differ by treatment group. Among children vaccinated with FFM ME-TRAP, there was no correlation between immunogenicity and malaria incidence.</p><p><strong>Conclusions: </strong>No protection was induced against febrile malaria by this vaccine regimen. Future field studies will require vaccinations with stronger immunogenicity in children living in malarious areas.</p>","PeriodicalId":87416,"journal":{"name":"PLoS clinical trials","volume":null,"pages":null},"PeriodicalIF":0.0000,"publicationDate":"2006-10-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1371/journal.pctr.0010029","citationCount":"160","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"PLoS clinical trials","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1371/journal.pctr.0010029","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 160

Abstract

Objective: The objective was to measure the efficacy of the vaccination regimen FFM ME-TRAP in preventing episodes of clinical malaria among children in a malaria endemic area. FFM ME-TRAP is sequential immunisation with two attenuated poxvirus vectors (FP9 and modified vaccinia virus Ankara), which both deliver the pre-erythrocytic malaria antigen construct multiple epitope-thrombospondin-related adhesion protein (ME-TRAP).

Design: The trial was randomised and double-blinded.

Setting: The setting was a rural, malaria-endemic area of coastal Kenya.

Participants: We vaccinated 405 healthy 1- to 6-year-old children.

Interventions: Participants were randomised to vaccination with either FFM ME-TRAP or control (rabies vaccine).

Outcome measures: Following antimalarial drug treatment children were seen weekly and whenever they were unwell during nine months of monitoring. The axillary temperature was measured, and blood films taken when febrile. The primary analysis was time to a parasitaemia of over 2,500 parasites/mul.

Results: The regime was moderately immunogenic, but the magnitude of T cell responses was lower than in previous studies. In intention to treat (ITT) analysis, time to first episode was shorter in the FFM ME-TRAP group. The cumulative incidence of febrile malaria was 52/190 (27%) for FFM ME-TRAP and 40/197 (20%) among controls (hazard ratio = 1.52). This was not statistically significant (95% confidence interval [CI] 1.0-2.3; p = 0.14 by log-rank). A group of 346 children were vaccinated according to protocol (ATP). Among these children, the hazard ratio was 1.3 (95% CI 0.8-2.1; p = 0.55 by log-rank). When multiple malaria episodes were included in the analyses, the incidence rate ratios were 1.6 (95% CI 1.1-2.3); p = 0.017 for ITT, and 1.4 (95% CI 0.9-2.1); p = 0.16 for ATP. Haemoglobin and parasitaemia in cross-sectional surveys at 3 and 9 mo did not differ by treatment group. Among children vaccinated with FFM ME-TRAP, there was no correlation between immunogenicity and malaria incidence.

Conclusions: No protection was induced against febrile malaria by this vaccine regimen. Future field studies will require vaccinations with stronger immunogenicity in children living in malarious areas.

Abstract Image

Abstract Image

Abstract Image

候选疟疾疫苗FP9 ME-TRAP和MVA ME-TRAP在肯尼亚儿童中的2b期随机试验
目的:目的是衡量疫苗接种方案FFM ME-TRAP在预防疟疾流行地区儿童临床疟疾发作中的效果。FFM ME-TRAP是用两种减毒痘病毒载体(FP9和修饰的安卡拉痘苗病毒)进行序次免疫,这两种载体均递送红细胞前疟疾抗原构建多表位-血小板相关粘附蛋白(ME-TRAP)。设计:试验采用随机双盲法。研究地点:研究地点是肯尼亚沿海疟疾流行的农村地区。参与者:我们为405名1至6岁的健康儿童接种了疫苗。干预措施:参与者被随机分配接种FFM ME-TRAP或对照组(狂犬病疫苗)。结果测量:在9个月的监测期间,接受抗疟药物治疗的儿童每周接受一次检查,每当他们感到不适时接受检查。测量腋窝温度,发热时取血片。初步分析结果显示,每匹马有2500多只寄生虫。结果:该方案具有中度免疫原性,但T细胞反应的强度低于先前的研究。在意向治疗(ITT)分析中,FFM ME-TRAP组到首次发作的时间更短。热性疟疾累积发病率FFM ME-TRAP组为52/190(27%),对照组为40/197(20%)(风险比= 1.52)。这没有统计学意义(95%置信区间[CI] 1.0-2.3;log-rank P = 0.14)。一组346名儿童根据方案(ATP)接种了疫苗。在这些儿童中,风险比为1.3 (95% CI 0.8-2.1;log-rank P = 0.55)。当分析中包括多次疟疾发作时,发病率比为1.6 (95% CI 1.1-2.3);ITT的p = 0.017, 1.4 (95% CI 0.9-2.1);ATP p = 0.16。在3月和9月的横断面调查中,血红蛋白和寄生虫血症在治疗组之间没有差异。在接种了FFM ME-TRAP疫苗的儿童中,免疫原性与疟疾发病率之间没有相关性。结论:该疫苗方案对热性疟疾无保护作用。未来的实地研究将需要对生活在疟疾地区的儿童进行免疫原性更强的疫苗接种。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
自引率
0.00%
发文量
0
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信